Cannabis Law Report

AUGUST 24, 2021

Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19. Forward Looking Information. TORONTO–(BUSINESS WIRE)–FSD Pharma Inc.

Clinical Trials 105

Clinical Trials Treatment Pharmaceutical Concentrates 105

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial. Visit [link].

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

NORML

APRIL 30, 2020

CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.” ” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients. percent in 2016).”

Chronic Pain 341

Chronic Pain Clinical Trials Data Patients 341

NORML

MARCH 30, 2020

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. Misleading claims represent both a threat to public health and a violation of consumer access to accurate information.”

CBD 295

CBD Clinical Trials Data Treatment 295

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. For more information, visit the company’s website or download their investor presentation. MedXtractor Corp.’s Looking Ahead.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Medical Marijuana Program Connection

FEBRUARY 27, 2023

The cannabis oil will be used as a part of the Company‘s proprietary SCI-210 treatment combination of CBD and CannAmide™ TEL. Read More

Clinical Trials 52

Clinical Trials Oil CBD Treatment 52

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial. Visit [link].

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

NORML

JANUARY 31, 2019

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

Clinical Trials 193

Clinical Trials Chronic Pain Data Treatment 193

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In part of one of this series, we analyzed the discussions surrounding using cannabis for mental health. In part two, we took a deep look at using cannabis for depression. In part three, we will analyze the available research concerning cannabis and anxiety. Can you use cannabis for anxiety? Cannabis and Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

CannaMD

JUNE 2, 2021

However, little is known about these patients’ thoughts and experiences related to cannabis, or its perceived effect on the disease’s symptoms. In addition, cannabis users participating in the survey were younger by an average of 3 years in age than non-users in the survey. Why Do Parkinson’s Patients Use Marijuana?

Patients 105

Patients Clinical Trials Treatment Research and Development 105

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain.

Data 105

Data Clinical Trials Research and Development Indica 105

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Canna Care Docs

OCTOBER 3, 2023

As a devastating diagnosis, patients with a terminal illness must not only learn to cope with this information about their health but find restorative ways to alleviate the most common symptoms and effects. However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Medicinal Marijuana Association

FEBRUARY 11, 2024

You may have heard whispers of cannabis being used to address a specific eye condition, but what does the research truly reveal about its effectiveness? The potential link between cannabis and glaucoma treatment is a topic of ongoing investigation, stirring both curiosity and caution within the medical community.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

Veriheal

FEBRUARY 9, 2023

Although many rely on imaging scans to diagnose illnesses and get treatment of various kinds, getting into the enclosed chamber can be stressful. A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. 9,199,960). USOTC: USMJ).

Treatment 52

Treatment Research and Development CBD eCommerce 52

The Cannigma

MARCH 18, 2021

The majority of people with Parkinson’s disease in the United States have not used cannabis to treat their symptoms due to a lack of scientific evidence about its effectiveness. Of those who have used cannabis, most did not receive a recommendation from a doctor or instructions on how to use it, according to the findings of a recent study.

Patients 138

Patients Clinical Trials Treatment Cannabis 138

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

PrestoDoctor

SEPTEMBER 15, 2023

While there are a variety of treatments available, many individuals do not find relief with traditional medications or therapies. However, recent research suggests that cannabis may be a promising option for those seeking relief from OCD symptoms. It is a serious medical condition that requires appropriate treatment and support.

Research and Development 105

Research and Development Therapy Treatment Strains 105

The Cannigma

FEBRUARY 2, 2021

This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

AUGUST 10, 2022

MediPharm to design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., ” Study Details – provided by Alzheimer’s Clinical Trial Consortium. .” across 20 sites.

Clinical Trials 52

Clinical Trials Medicine Pharmaceutical THC 52

Veriheal

JULY 16, 2020

The commission tasked with developing recommendations to improve mental health treatment for veterans concluded: Congress and the executive branch need to promote research into the therapeutic potential of cannabis and psychedelics such as psilocybin mushrooms and MDMA. The Commission Focused on Veteran Well-being.

Research and Development 96

Research and Development Clinical Trials Treatment Compliance 96

Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The researchers’ analysis found anxiety was the reason given for 16% of medicinal cannabis prescriptions. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

PrestoDoctor

OCTOBER 11, 2023

For years, the use of cannabis has been a controversial topic. One area of research that has been gaining attention is the use of CBD-rich cannabis in treating the social symptoms of Autism Spectrum Disorder (ASD). One such area of focus is the use of CBD-rich cannabis. What is CBD?

CBD 52

CBD Research and Development Clinical Trials Treatment 52

Cannabis Law Report

JULY 27, 2021

The ORR is a web-based research platform open to adults and adult caregivers of dependents who are, or are considering, the use of cannabis or hemp products for therapeutic purposes. There are numerous obstacles to exploring the therapeutic potential of cannabis due to its classification as a Schedule I controlled substance,” Schlienz said.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

NOVEMBER 23, 2021

The new patent, US Patent No 11,180,517, covers methods of treating treatment-resistant depression (TRD) with crystalline psilocybin as well as with oral dosage forms of crystalline psilocybin with an excipient. Availability of other information about COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Veriheal

MAY 26, 2022

With new and improved products popping up left and right, legalization initiatives taking off all over the globe, and harmful “stoner” stigmas quickly dissipating, it’s clear that cannabis has entered a new era. The days of “reefer madness” are long over, replaced by a growing acknowledgment of the cannabis plant’s therapeutic abilities.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Veriheal

MAY 3, 2022

Cannabis use disorder (CUD) is often confused with frequent cannabis use , but CUD is significantly more worrisome. The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98